◀ Back to EGFR

CBL — EGFR

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: EGFR → Complex of CBL-EGFR (decreases) Khan et al., FASEB J 2008*
  Evidence: On EGFR activation, c-Cbl associates with phosphorylated Tyr-1045 and ubiquitinates the receptor, marking it for clathrin-mediated endocytosis and recognition by the lysosomal machinery, which results in receptor degradation and signal termination (3–6).
• OpenBEL Selventa BEL large corpus: EGFR → CBL (increases, CBL Translocation, EGFR Activity) Soubeyran et al., Nature 2002
  Evidence: Cbl rapidly recruits CIN85 (Cbl-interacting protein of 85K; ref. 6) and endophilins (regulatory components of clathrin-coated vesicles) to form a complex with activated EGF receptors, thus controlling receptor internalization.
• OpenBEL Selventa BEL large corpus: CBL → EGFR (directlyIncreases, CBL Activity)
  Evidence: phosphorylation of c-Cbl on tyrosine 371 by the activated EGFR
• OpenBEL Selventa BEL large corpus: CBL → EGFR (directlyIncreases, CBL Activity)
  Evidence: 10635327;11997497
• OpenBEL Selventa BEL large corpus: CBL → EGFR (increases, CBL Activity)
  Evidence: This is taken from supplemental table 2 from PMID 15951569 Cut-offs were 2.25 for increase and 0.5 for decrease LLID were found by converting from GI assession numbers in DAVID Spreadsheet is saved in the project folder for Cell Signaling Project # bduckworth
• BioCarta cbl mediated ligand-induced downregulation of egf receptors pathway: EGF R/SRC/EGF complex (EGFR-SRC-EGF) → CBL (protein ubiquitination, collaborate)
• KEGG Endocytosis: CBL/CBLB/CBLC/ITCH/MDM2/NEDD4/NEDD4L/RNF41/SMURF1/SMURF2/TRAF6/WWP1 → CSF1R/EGFR/ERBB3/ERBB4/FGFR2/FGFR3/FGFR4/FLT1/IGF1R/KDR/KIT/MET/NTRK1/PDGFRA/RET (protein-protein, ubiquination)
  
• KEGG ErbB signaling pathway: Complex of EGFR → CBL/CBLB/CBLC (protein-protein, activation)
• NCI Pathway Database Internalization of ErbB1: CBL/Ubc4-5 family complex (CBL-UBE2D2_UBE2D3_UBE2D1) → EGFR/EGFR/EGF/EGF complex (EGFR-EGF) (modification, activates)
  Grøvdal et al., Exp Cell Res 2004, Umebayashi et al., Mol Biol Cell 2008
  Evidence: physical interaction
• NCI Pathway Database Internalization of ErbB1: EGFR/EGFR/EGF/EGF/GRB2/CBL complex (EGFR-EGF-GRB2-CBL) → EGFR/EGFR/EGF/EGF complex (EGFR-EGF) (modification, collaborate)
  
• NCI Pathway Database Internalization of ErbB1: EGFR/EGFR/EGF/EGF/GRB2/CBL complex (EGFR-EGF-GRB2-CBL) → GRB2/CBL complex (GRB2-CBL) (modification, collaborate)
  
• NCI Pathway Database Internalization of ErbB1: EGFR/EGFR/EGF/EGF complex (EGFR-EGF) → GRB2/CBL complex (GRB2-CBL) (modification, collaborate)
  
• NCI Pathway Database Internalization of ErbB1: EGFR/EGFR/EGF/EGF complex (EGFR-EGF) → EGFR/EGFR/EGF/EGF/GRB2/CBL complex (EGFR-EGF-GRB2-CBL) (modification, collaborate)
  Levkowitz et al., Mol Cell 1999, Waterman et al., EMBO J 2002, Jiang et al., Mol Biol Cell 2003*, Jiang et al., Traffic 2003*, Huang et al., Mol Biol Cell 2005, Huang et al., Proc Natl Acad Sci U S A 2007*
  Evidence: physical interaction
• NCI Pathway Database Internalization of ErbB1: EGFR/EGFR/EGF/EGF complex (EGFR-EGF) → GRB2/CBL complex (GRB2-CBL) (modification, collaborate)
  Levkowitz et al., Mol Cell 1999, Waterman et al., EMBO J 2002, Jiang et al., Mol Biol Cell 2003*, Jiang et al., Traffic 2003*, Huang et al., Mol Biol Cell 2005, Huang et al., Proc Natl Acad Sci U S A 2007*
  Evidence: physical interaction
• NCI Pathway Database Internalization of ErbB1: EGFR/EGFR/EGF/EGF/GRB2/CBL complex (EGFR-EGF-GRB2-CBL) → GRB2/CBL complex (GRB2-CBL) (modification, collaborate)
  Levkowitz et al., Mol Cell 1999, Waterman et al., EMBO J 2002, Jiang et al., Mol Biol Cell 2003*, Jiang et al., Traffic 2003*, Huang et al., Mol Biol Cell 2005, Huang et al., Proc Natl Acad Sci U S A 2007*
  Evidence: physical interaction
• Reactome Reaction: CBL → EGFR (indirect_complex) Joazeiro et al., Science 1999, Waterman et al., EMBO J 2002, Marmor et al., Oncogene 2004, Sordella et al., Science 2004, Greulich et al., PLoS Med 2005, Yang et al., Cancer Res 2006, Choi et al., Oncogene 2007, Han et al., Cancer Biol Ther 2006, Lee et al., PLoS Med 2006, Grandal et al., Carcinogenesis 2007*, Padrón et al., Cancer Res 2007, Xu et al., Br J Cancer 2007
• Reactome Reaction: CBL → EGFR (direct_complex) Joazeiro et al., Science 1999, Rosenthal et al., J Biol Chem 1999, Soubeyran et al., Nature 2002, Klapisz et al., J Biol Chem 2002, Haglund et al., Proc Natl Acad Sci U S A 2002, Marmor et al., Oncogene 2004, Kassenbrock et al., J Biol Chem 2004, Grøvdal et al., Exp Cell Res 2004, Sigismund et al., Proc Natl Acad Sci U S A 2005, Haglund et al., EMBO Rep 2005, Schmidt et al., Oncogene 2006, Galisteo et al., J Biol Chem 1995*
• Reactome Reaction: CBL → EGFR (reaction) Joazeiro et al., Science 1999, Waterman et al., EMBO J 2002, Haglund et al., Proc Natl Acad Sci U S A 2002, Hall et al., Curr Biol 2003, Marmor et al., Oncogene 2004, Kassenbrock et al., J Biol Chem 2004, Sordella et al., Science 2004, Grøvdal et al., Exp Cell Res 2004, Greulich et al., PLoS Med 2005, Schmidt et al., Oncogene 2006, Yang et al., Cancer Res 2006, Choi et al., Oncogene 2007, Han et al., Cancer Biol Ther 2006, Lee et al., PLoS Med 2006, Grandal et al., Carcinogenesis 2007*, Padrón et al., Cancer Res 2007, Xu et al., Br J Cancer 2007, Galisteo et al., J Biol Chem 1995*
• WikiPathways ErbB Signaling Pathway: EGFR → CBL (activation)
• WikiPathways Signaling Pathways in Glioblastoma: CBL → IGF1R/ERBB3/FGFR1/PDGFRA/PDGFRB/ERBB2/EGFR/FGFR2/MET (mim-inhibition)
  
• WikiPathways Association Between Physico-Chemical Features and Toxicity Associated Pathways: EGFR → CBL (activation)

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Bind Interaction: CBL — EGFR Bowtell et al., Oncogene 1995*, Meisner et al., J Biol Chem 1995*, Galisteo et al., J Biol Chem 1995*
• IRef Bind_translation Interaction: CBL — EGFR (coimmunoprecipitation) Bowtell et al., Oncogene 1995*, Meisner et al., J Biol Chem 1995*
• IRef Bind_translation Interaction: CBL — EGFR (coimmunoprecipitation) Zhang et al., Oncogene 2005*
• IRef Bind_translation Interaction: CBL — EGFR (affinity chromatography technology) Schulze et al., Molecular systems biology 2005
• IRef Bind_translation Interaction: CBL — EGFR (experimental interaction detection) Wong et al., EMBO J 2002*
• IRef Bind_translation Interaction: CBL — EGFR (coimmunoprecipitation) Bowtell et al., Oncogene 1995*
• IRef Bind_translation Interaction: CBL — EGFR (experimental interaction detection) Bowtell et al., Oncogene 1995*, Galisteo et al., J Biol Chem 1995*
• IRef Bind_translation Interaction: CBL — EGFR (coimmunoprecipitation) Bowtell et al., Oncogene 1995*, Galisteo et al., J Biol Chem 1995*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Gui et al., BMC cancer 2012*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Crovello et al., J Biol Chem 1998
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Graus-Porta et al., EMBO J 1997
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Oksvold et al., Eur J Cell Biol 2001*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Raguz et al., FEBS Lett 2007*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Thien et al., Mol Cell 2001*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) de Melker et al., J Cell Sci 2004*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Burke et al., Mol Biol Cell 2001
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Kassenbrock et al., J Biol Chem 2004
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Schroeder et al., Mol Biol Cell 2012*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Tarcic et al., Curr Biol 2009*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Shen et al., Mol Biol Cell 2007*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Adachi et al., Carcinogenesis 2009*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Mitsushima et al., Genes Cells 2006*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Choi et al., Mol Cells 2003*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Tanaka et al., J Biol Chem 1995*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Meisner et al., J Biol Chem 1995*
• IRef Biogrid Interaction: CBL — EGFR (direct interaction, pull down) Kumar et al., J Med Chem 2012*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Tong et al., J Proteome Res 2008
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Scott et al., J Biol Chem 2005*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Meijer et al., Cell Signal 2013*
• IRef Biogrid Interaction: CBL — EGFR (direct interaction, enzymatic study) Levkowitz et al., Mol Cell 1999
• IRef Biogrid Interaction: CBL — EGFR (direct interaction, enzymatic study) Dou et al., Nature structural & molecular biology 2012*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Levkowitz et al., Mol Cell 1999
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Bode et al., Cancer Res 2009*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Thomas et al., Breast Cancer Res 2012*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Chang et al., Cell Death Differ 2013*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Gan et al., Oncogene 2010*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Smith et al., J Cell Sci 2013
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Fukazawa et al., J Biol Chem 1996
• IRef Biogrid Interaction: CBL — EGFR (direct interaction, pull down) Fukazawa et al., J Biol Chem 1996
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Wang et al., PloS one 2013*
• IRef Biogrid Interaction: CBL — EGFR (direct interaction, enzymatic study) Sigismund et al., EMBO J 2013*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Sigismund et al., EMBO J 2013*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Hong et al., Cancer Res 2013*
• IRef Biogrid Interaction: CBL — EGFR (direct interaction, pull down) Sigismund et al., EMBO J 2013*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Kondratov et al., Cell Biol Int 2010*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Odintsova et al., J Biol Chem 2013*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Meisner et al., Mol Cell Biol 1997*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) de Melker et al., J Biol Chem 2004*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Miraoui et al., Hum Mol Genet 2010*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Ettenberg et al., Oncogene 1999*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Tvorogov et al., Exp Cell Res 2002*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Khan et al., FASEB J 2008*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Pennock et al., Mol Cell Biol 2008*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Umebayashi et al., Mol Biol Cell 2008
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Povlsen et al., J Neurochem 2008*
• IRef Biogrid Interaction: CBL — EGFR (association, x-ray crystallography) Ng et al., EMBO J 2008
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Ng et al., EMBO J 2008
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Dey et al., Journal of oncology 2011*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Yang et al., Cancer Res 2006
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Su et al., J Biol Chem 2007*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Gur et al., EMBO J 2004*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Han et al., Cancer Biol Ther 2006
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Shtiegman et al., Oncogene 2007*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Visser et al., Exp Cell Res 2005*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Tsacoumangos et al., J Cell Sci 2005*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Prasad et al., J Biol Chem 2005*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Feshchenko et al., Oncogene 2004*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Kowanetz et al., J Biol Chem 2004*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Wu et al., Cell 2003*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Bonaccorsi et al., J Mol Endocrinol 2007*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Schmidt et al., Proc Natl Acad Sci U S A 2003*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Rubin et al., Curr Biol 2003
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Bao et al., Proc Natl Acad Sci U S A 2003*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Waterman et al., J Biol Chem 1999*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Guo et al., Glycobiology 2009*
• IRef Biogrid Interaction: CBL — EGFR (direct interaction, pull down) Tong et al., Mol Cell Proteomics 2009
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Tong et al., Mol Cell Proteomics 2009
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Ravid et al., J Biol Chem 2004
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Sanada et al., Circ Res 2009*
• IRef Biogrid Interaction: CBL — EGFR (direct interaction, pull down) Sun et al., PloS one 2010*
• IRef Biogrid Interaction: CBL — EGFR (colocalization, imaging technique) Ravid et al., J Biol Chem 2004
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Rafiq et al., J Biol Chem 2012*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Haglund et al., EMBO Rep 2005
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Duan et al., J Biol Chem 2011*
• IRef Biogrid Interaction: CBL — EGFR (physical association, affinity chromatography technology) Oksvold et al., Oncogene 2003*
• MIPS CORUM CIN85-CBL-SH3GL2-EGFR complex, EGF stimulated: CIN85-CBL-SH3GL2-EGFR complex, EGF stimulated complex (CBL-EGFR-SH3KBP1) Soubeyran et al., Nature 2002
• MIPS CORUM EGFR-CBL-GRB2 complex: EGFR-CBL-GRB2 complex complex (CBL-EGFR-GRB2) Galperin et al., Nat Methods 2004*
• IRef Corum Interaction: Complex of CBL-EGFR-SH3KBP1 (association, coimmunoprecipitation) Soubeyran et al., Nature 2002
• IRef Corum Interaction: Complex of EGFR-CBL-GRB2 (association, fluorescent resonance energy transfer) Galperin et al., Nat Methods 2004*
• IRef Dip Interaction: Complex of UBA52-EGFR-CBLB-CBL (anti bait coimmunoprecipitation) Vivanco et al., Proc Natl Acad Sci U S A 2010*
• IRef Dip Interaction: CBL — EGFR (physical association, anti bait coimmunoprecipitation) Vivanco et al., Proc Natl Acad Sci U S A 2010*
• IRef Hprd Interaction: Complex of 17 proteins (in vivo) Soubeyran et al., Nature 2002, Szymkiewicz et al., J Biol Chem 2002
• IRef Hprd Interaction: CBL — EGFR (in vivo) Howlett et al., Biochem Biophys Res Commun 1999*, Scholz et al., J Biol Chem 2000*, Thien et al., Mol Cell 2001*, Kassenbrock et al., J Biol Chem 2002*, Schulze et al., Molecular systems biology 2005, Ng et al., EMBO J 2008, Galisteo et al., J Biol Chem 1995*, Fukazawa et al., J Biol Chem 1996, Lupher et al., J Biol Chem 1996*, Hunter et al., J Biol Chem 1999*
• IRef Hprd Interaction: CBL — EGFR (in vitro) Howlett et al., Biochem Biophys Res Commun 1999*, Scholz et al., J Biol Chem 2000*, Thien et al., Mol Cell 2001*, Kassenbrock et al., J Biol Chem 2002*, Schulze et al., Molecular systems biology 2005, Ng et al., EMBO J 2008, Galisteo et al., J Biol Chem 1995*, Fukazawa et al., J Biol Chem 1996, Lupher et al., J Biol Chem 1996*, Hunter et al., J Biol Chem 1999*
• IRef Intact Interaction: Complex of SH3KBP1-CBL-SH3GL2-EGFR (association, anti bait coimmunoprecipitation) Soubeyran et al., Nature 2002
• IRef Intact Interaction: Complex of ITSN1-CBL-EGFR (colocalization, fluorescence microscopy) Martin et al., Mol Pharmacol 2006*
• IRef Intact Interaction: Complex of 70 proteins (association, anti bait coimmunoprecipitation) Thelemann et al., Mol Cell Proteomics 2005
• IRef Intact Interaction: CBL — EGFR (physical association, anti bait coimmunoprecipitation) Haglund et al., EMBO Rep 2005
• IRef Intact Interaction: CBL — EGFR (physical association, pull down) Scott et al., J Biol Chem 2005*
• IRef Intact Interaction: CBL — EGFR (physical association, pull down) Schulze et al., Molecular systems biology 2005
• IRef Intact Interaction: CBL — EGFR (physical association, anti bait coimmunoprecipitation) Ng et al., EMBO J 2008
• IRef Intact Interaction: CBL — EGFR (direct interaction, x-ray crystallography) Ng et al., EMBO J 2008
• IRef Intact Interaction: CBL — EGFR (direct interaction, isothermal titration calorimetry) Ng et al., EMBO J 2008
• IRef Intact Interaction: CBL — EGFR (physical association, anti bait coimmunoprecipitation) Gan et al., Oncogene 2010*
• IRef Intact Interaction: CBL — EGFR (direct interaction, far western blotting) Galisteo et al., J Biol Chem 1995*
• IRef Intact Interaction: CBL — EGFR (physical association, coimmunoprecipitation) Fukazawa et al., J Biol Chem 1996
• IRef Ophid Interaction: CBL — EGFR (aggregation, interologs mapping) Brown et al., Bioinformatics 2005
• IRef Ophid Interaction: CBL — EGFR (aggregation, confirmational text mining) Fukazawa et al., J Biol Chem 1996

Text-mined interactions from Literome

Lill et al., J Biol Chem 2000 : Overexpression of wild-type Cbl enhances down-regulation of activated EGF-R from the cell surface ... Whereas wild-type Cbl enhanced ligand dependent EGF-R ubiquitination, down-regulation from the cell surface, accumulation in intracellular vesicles, and degradation, a Cbl TKB domain inactivated mutant ( G306E ) did not ... Therefore, Cbl mediated down-regulation of EGF-R requires the integrity of both the N-terminal TKB domain and additional C-terminal sequences
Waterman et al., EMBO J 2002 : Ligand induced desensitization of the epidermal growth factor receptor (EGFR) is controlled by c-Cbl , a ubiquitin ligase that binds multiple signaling proteins, including the Grb2 adaptor
Duan et al., J Biol Chem 2003 : However, the role of endogenous Cbl in EGFR down-regulation and the precise step in the endocytic pathway regulated by Cbl remain unclear ... Using Cbl-/- mouse embryonic fibroblast cell lines, we demonstrate that endogenous Cbl is essential for ligand induced ubiquitinylation and efficient degradation of EGFR ... Further analyses using Chinese hamster ovary cells with a temperature-sensitive defect in ubiquitinylation confirm a crucial role of the ubiquitin machinery in Cbl mediated EGFR degradation
Jiang et al., Traffic 2003 : These data suggest that the binding of Cbl to epidermal growth factor receptor through Grb2 is necessary and sufficient for Cbl function during clathrin mediated endocytosis
Ohkawa et al., Int J Oncol 2004 (Carcinoma, Squamous Cell) : These phenomena can be regarded as one of the causes of prevention of c-Cbl mediated down-regulation of EGFR in variant cells, enabling them to live
Zhang et al., Oncogene 2005 : This novel result suggests that HPV16 E5 may, at least in part, upregulate EGFR mediated signal transduction by inhibiting the interaction of c-Cbl with the EGFR, thereby decreasing c-Cbl mediated degradation of the EGFR
Hirsch et al., Cancer Res 2006 (Breast Neoplasms) : In NIH3T3 fibroblasts, active Cdc42 inhibits c-Cbl regulated EGFR degradation to induce cellular transformation ... Here, we use two EGFR overexpressing breast cancer cell lines, MDA-MB-231 and BT20, as models to test the hypothesis that up-regulated Cdc42 activity impairs c-Cbl mediated EGFR degradation and contributes to EGFR overexpression ... We show that silencing Cdc42 significantly reduces protein levels of EGFR, leading to a marked reduction in cell proliferation and migration, and c-Cbl knockdown increases the levels of EGFR ... Moreover, down-regulated EGFR signaling induced by c-Cbl-N480 decreased activity of Cdc42 and Rac1, resulting in inhibition of cell migration
Swaminathan et al., J Cell Physiol 2006 (Cell Transformation, Neoplastic) : The major sections of the review are as follows : Structure and genomic organization of Cbl proteins ; Phosphorylation of Cbl ; Interactions of Cbl ; Localization of Cbl ; Mechanism of effects of Cbl : ( a ) Ubiquitylation dependent events : This section elucidates the mechanism of Cbl mediated downregulation of EGFR and details the PTK and non-PTKs targeted by Cbl
Mitsushima et al., Genes Cells 2006 : Furthermore, over-expression of c-Cbl suppressed the sustained phosphorylation of EGFR induced by vinexin beta
Stern et al., Mol Cell Biol 2007 : By modulating Hrs ubiquitination, phosphorylation, and protein levels, Cbl may control the composition of the endosomal sorting machinery and its ability to target EGFR for lysosomal degradation
Hirsch et al., Expert Rev Anticancer Ther 2007 (Breast Neoplasms) : Increasing evidence suggests that loss of Cbl regulated ErbB1 degradation contributes to ErbB1 overexpression in cancer cells
Padrón et al., Cancer Res 2007 (Carcinoma, Non-Small-Cell Lung...) : Overexpression of Cbl increased the degradation of EGFR
Lito et al., J Biol Chem 2008 (Cell Transformation, Neoplastic...) : Interestingly, Spry2 also prevents the c-Cbl induced degradation of epidermal growth factor receptor (EGFR)
Jung et al., J Cell Physiol 2010 (Neoplasms) : Finally, quercetin increased the interaction between EGFR and Cbl, and also induced the tyrosine phosphorylation of Cbl
Ahsan et al., Cancer Res 2010 (Head and Neck Neoplasms) : Transfection of WT c-Cbl enhanced EGFR degradation and cisplatin induced cytotoxicity compared with control vector
Lee et al., J Cell Biochem 2010 (Glioma...) : We demonstrate that the observed role of c-Cbl in invasion of SNB19 cells is not mediated by the previously shown effects of c-Cbl on cell adhesion and migration or on EGFR signaling
Wakasaki et al., Neoplasia (New York, N.Y.) 2010 (Carcinoma, Squamous Cell...) : Little is known, however, about a role of CIN85 in EGFR signaling as well as its relevance to tumor development and progression of HNSCC
Yoon et al., Biol Cell 2011 : Overexpression of ARAP1 reduced ubiquitination of the EGFR by Cbl and slowed Cbl dependent degradation of the EGFR
Wang et al., PloS one 2011 : D-Cbl binding to Drk leads to dose dependent down-regulation of EGFR signaling and increases receptor-ligand endocytosis
Rafiq et al., J Biol Chem 2012 : Interestingly, c-Cbl activation induced by Cat.G was mediated through epidermal growth factor receptor (EGFR) transactivation as inhibition of EGFR kinase activity markedly attenuated c-Cbl phosphorylation and FA protein degradation induced by Cat.G
Schroeder et al., Mol Biol Cell 2012 : In this study we show that EGFR activation leads to a pronounced src mediated tyrosine phosphorylation of CIN85 that subsequently influences EGFR ubiquitination
Wang et al., PloS one 2012 (Carcinoma, Hepatocellular...) : Furthermore, forced expression of both ephrinA5 isoforms in HCC cell lines significantly down-regulated epidermal growth factor receptor (EGFR) expression by promoting c-Cbl mediated EGFR degradation
Rodriguez et al., FASEB J 2013 (Neoplasms) : Moreover, the tumor suppressor phosphatase and tensin homolog (PTEN) was shown to modulate c-Cbl dependent EGFR degradation
Wang et al., PloS one 2013 (Colonic Neoplasms) : Knock-down Cbl expression blocked the effects of berberine on down-regulation of EGFR and inhibition of proliferation
Rajendran et al., Asian Pac J Cancer Prev 2013 : Loss of expression or function of c-Cbl may consequently lead to sustained activation of EGFR and promote carcinogenesis, loss of function mutations in the c-Cbl gene already being reported in lung and hematopoietic cancers
Tushar et al., Asian Pac J Cancer Prev 2013 (Carcinoma, Squamous Cell...) : After having transduced extracellular growth activating signals, activated EGFR is subjected to downregulation either by clathrin mediated endocytosis or c-Cbl mediated proteasome degradation depending on the ligand concentration
Ueno et al., J Biol Chem 1997 : In this study, by an antisense RNA approach, we examined the effects of expression level of c-Cbl on EGFR signaling and showed that overexpression of c-Cbl reduces and antisense repression of c-Cbl enhances autophosphorylation of EGF receptors and activation of the JAK-STAT pathway